Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma - 04/09/15
The DREAM study (ClinicalTrials.gov, no. NCT01000506) was funded by GlaxoSmithKline. |
|
Disclosure of potential conflict of interest: H. Ortega, N. Gunsoy, O. Keene, and S. Yancey are employed by GlaxoSmithKline. L. Katz was employed by GlaxoSmithKline until April 2015. All of the authors have stock/stock options in GlaxoSmithKline. |
|
Editor's note:There is no accompanying reply to this correspondence. |
Vol 136 - N° 3
P. 825-826 - septembre 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?